medigraphic.com
ISSN 0016-3813 (Print)

2004, Number S2

<< Back Next >>

Gac Med Mex 2004; 140 (S2)

Obesity has been associated with development of Criptogenic cirrhosis and Hepatocarcinoma

Lizardi-Cervera J, Motola-Kuba D, Guevara-González L

Language: Spanish
References: 42
Page: 77-84
PDF size: 545.24 Kb.


ABSTRACT

Obesity is a rapidly growing health issue in Mexico and throughout the world because it is perceived as an alarming threat directly related with lifestyle in both children and adults, although cardiovascular, metabolic, neoplasic, and sleep-disorder complications of obesity are being investigated. However, overweight is a risk factor for chronic liver disease because liver fibrosis can develop in overweight patients free of any other known causes of liver disease. Obesity has been associated with development of hepatocellular carcinoma.


REFERENCES

  1. Ayata G, Gordon FD, Lewis WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002;33:1098-104.

  2. Clark J, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289:3000-4.

  3. Méndez-Sánchez M, Sánchez-Castillo CP, Villa AR, Madrigal H, Merino B, García E, López P, Pichardo-Ontiveros E, Uribe M. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. Ann Hepatol 2004;3:66-71.

  4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.

  5. Kodali VP, Gordon SC, Silverman AL, McCray DG. Cryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis. Am J Gastroenterol 1994;89:1836-9.

  6. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004;40:578-84.

  7. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004;3:30-3.

  8. Geller SA. Hepatitis B and hepatitis C. Clin Liver Dis 2002;6:317-34, v.

  9. Flamm SL. Chronic hepatitis C virus infection. JAMA 2003;289:2413-7.

  10. Lemberg BD, Shaw-Stiffel TA. Hepatic disease in injection drug users. Infect Dis Clin North Am 2002;16:667-79.

  11. Cohen J, Powderly WG, Berkley SF, et al. Infectious diseases. New York, NY, USA:Mosby;2004.

  12. Mandell GL, Bennett JE, Dolin R. Mandell: Principles and practice of infectious diseases. Philadelphia, PA, USA: Churchill Livingstone, Inc.;2000.

  13. Feldman M, Tschumy WO, Friedman L, Sleisenger MH. Sleisenger & Fordtran’s gastrointestinal and liver disease: pathophysiology/diagnosis/management. Philadelphia, PA, USA: Elsevier;2002.

  14. Cairns SR, Peters TJ. Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clin Sci (Lond) 1983;65:645-52.

  15. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-7.

  16. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-7.

  17. Nakao K, Nakata K, Ohtsubo N, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002;97:1796-801.

  18. Méndez-Sánchez N, Chávez-Tapia NC, Uribe M. [An update on non-alcoholic fatty liver disease]. Rev Invest Clin 2004;56:72-82 (en español).

  19. Méndez-Sánchez N, Uribe M. Obesidad. Epidemiología, fisiopatología y nanifestaciones clínicas. Mexico, D.F.: El Manual Moderno;2002.

  20. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272:205-11.

  21. Arroyo P, Loría A, Fernández V, et al. Prevalence of preobesity and obesity in urban adult Mexicans in comparison with other large surveys. Obes Res 2000;8:179-85.

  22. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-23.

  23. Li Z, Clark J, Diehl AM. The liver in obesity and type 2 diabetes mellitus. Clin Liver Dis 2002;6:867-77.

  24. Jonas MM. Nonalcoholic fatty liver disease. Adolesc Med 2004;15:159-173.

  25. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.

  26. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61.

  27. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.

  28. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.

  29. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.

  30. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87-107, vi.

  31. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.

  32. Hillebrand D, Sandowski S. Hepatocellular carcinoma. Clin Fam Pract 2000;2:79-97.

  33. Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Gastroenterol Clin North Am 2002;31:641-62.

  34. Cortés-Espinosa T, Mondragón-Sánchez R, Hurtado-Andrade H, Sánchez-Cisneros R. Hepatocellular carcinoma and hepatic cirrhosis in Mexico: a 25 year necroscopy review. Hepatogastroenterology 1997;44:1401-3.

  35. Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001;51:127-31.

  36. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001;61:5016-23.

  37. Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69-S73.

  38. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-5.

  39. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93.

  40. Bacon BR, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-9

  41. Matteoni CA, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.

  42. Angulo P, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999:30:1356-62.




2020     |     www.medigraphic.com